Revenue growing at 168% year-over-year and roughly 55% upside to the analyst price target frame a high-potential early-stage biotechnology story, but deeply negative free cash flow, a 34% short interest, and weak near-term price momentum mean the setup requires a patient holding posture rather than aggressive deployment.
Thesis pillars
- Triple Digit Revenue Growth→Stable
- Large Upside Favorable Risk Reward→Stable
- Deeply Negative Free Cash Flow→Stable
- +1 more pillar — see the Why tab for full reasoning
ImmunityBio, Inc. (IBRX) Stock Analysis
Range Bound setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $7.92: Risk below floor (1.7 < 3.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.4/10 and A.R:R 3.5:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 31%; Elevated put/call ratio: 2.21; Below-average business quality.
ImmunityBio is commercializing ANKTIVA (nogapendekin alfa inbakicept), an IL-15 receptor superagonist FDA-approved in April 2024 for BCG-unresponsive non-muscle-invasive bladder cancer, with conditional EU approval granted in February 2026. The company generated ~$113 million in... Read more
Sell if holding. Engine safety override at $7.92: Risk below floor (1.7 < 3.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.4/10 and A.R:R 3.5:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 31%; Elevated put/call ratio: 2.21; Below-average business quality. Chart setup: RSI 52 mid-range, Bollinger mid-band. Score 6.4/10, moderate confidence.
Passes 8/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 50d clear, semi cycle peak clear, materials cycle peak clear). Suitability: speculative.
About ImmunityBio, Inc.
About ImmunityBio, Inc.
ANKTIVA (nogapendekin alfa inbakicept), ImmunityBio's sole commercialized IL-15 receptor superagonist, generated approximately $113 million in net product revenue during fiscal 2025, representing roughly 700% year-over-year growth from its mid-2024 commercial launch following FDA approval in April 2024. The product has since received regulatory authorization in the UK (July 2025), conditional marketing authorization from the European Commission (February 2026), and two conditional approvals from Saudi Arabia's SFDA (January 2026), expanding the authorized footprint to 33 countries.
ImmunityBio generates product revenue from commercial sales of ANKTIVA to urology practices for intravesical treatment of BCG-unresponsive NMIBC, using the J-code (J9028) granted by CMS effective January 1, 2025, which expanded reimbursement to over 240 million covered lives as of December 2025. Distribution relies on third-party CMOs and wholesalers. A critical supply constraint exists: because ANKTIVA is indicated only in combination with BCG, and TICE BCG remains the only broadly available FDA-approved BCG strain in the U.S., any supply disruption to TICE BCG could directly curtail ANKTIVA utilization. Cash obligations are significant — the company carries a $505.0 million convertible promissory note held by an entity affiliated with founder Dr. Patrick Soon-Shiong and a revenue interest liability with Oberland exceeding $324.6 million under the RIPA, against $242.8 million in cash and marketable securities as of December 31, 2025.
Show full overview
A pending supplemental BLA for BCG-unresponsive NMIBC with papillary tumors represents a binary regulatory event for ImmunityBio. In May 2025, the FDA issued a Refuse to File letter recommending that the company submit additional information — potentially including data from a new randomized controlled trial — before accepting the sBLA for review. If a new RCT is required, the timeline to expand the NMIBC label beyond the CIS subgroup could extend materially, a meaningful constraint given the $3.7 billion accumulated deficit reported through December 31, 2025.
See also: Healthcare · Biotechnology
From ImmunityBio, Inc.'s most recent 10-K filing, extracted June 10, 2026.
Recent developments
updated 2026-09-14Recent Developments — ImmunityBio, Inc.
Latest news
- NEWS IBRX Stock Declines — ImmunityBio Resubmits Anktiva Application To FDA With Additional Data - Stocktwits — Stocktwits negative
- NEWS IBRX Stock Declines — ImmunityBio Resubmits Anktiva Application To FDA With Additional Data - stocktwits.com — stocktwits.com negative
- NEWS IBRX Stock Climbs After-Hours: Retail Traders Bet Russell 1000 Inclusion Could Trigger Massive Index-Fund Buying - stock — stocktwits.com positive
- NEWS IBRX Stock Extends 5-Day Losing Streak — Retail Traders Pin Hopes On ‘Incredibly Strong’ Anktiva Sales And Earnings Beat — TradingView positive
- NEWS IBRX stock in spotlight: ImmunityBio to unveil fresh Anktiva and BCG data next week - MSN — MSN positive
Generated 2026-09-14T07:17:02Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·2 ceiling hits
Volatile — 5.3% daily ATR makes tight stops impractical. Position-size conservatively.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $7.92: Risk below floor (1.7 < 3.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.4/10 and A.R:R 3.5:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 31%; Elevated put/call ratio: 2.21; Below-average business quality. Chart setup: RSI 52 mid-range, Bollinger mid-band. Prior stop was $7.36. Score 6.4/10, moderate confidence.
Take-profit target: $10.84 (+37.0% upside). Prior stop was $7.36. Stop-loss: $7.36.
Risk below floor (1.7 < 3.0).
ImmunityBio, Inc. trades at a P/E of N/A (forward -62.4). TrendMatrix value score: 9.0/10. Verdict: Sell.
10 analysts cover IBRX with a consensus score of 4.3/5. Average price target: $13.
What does ImmunityBio, Inc. do?ImmunityBio is commercializing ANKTIVA (nogapendekin alfa inbakicept), an IL-15 receptor superagonist FDA-approved in...
ImmunityBio is commercializing ANKTIVA (nogapendekin alfa inbakicept), an IL-15 receptor superagonist FDA-approved in April 2024 for BCG-unresponsive non-muscle-invasive bladder cancer, with conditional EU approval granted in February 2026. The company generated ~$113 million in net product revenue in 2025, representing roughly 700% year-over-year growth, against a $3.7 billion accumulated deficit as of December 31, 2025.